Dr Reddy's: Company launches patented molecule for acid-related gastrointestinal diseases
News by Aliceblue News Desk
17 Sept 2025
Introduction
Leading pharmaceutical company has introduced a novel molecule, Tegoprazan, in India for treating acid-related gastrointestinal diseases. The drug, launched under the brand PCAB®, offers fast action and prolonged gastric pH control benefits.
Also Read: Mishra Dhatu Nigam: Company receives new order worth ₹136 Cr
Share price movement of Dr. Reddy’s Laboratories
On September 17, 2025, Dr. Reddy’s Laboratories Ltd opened at ₹1,320.50, up 0.76% from its previous close of ₹1,310.55. The stock reached a high of ₹1,320.50 (0.76%) and a low of ₹1,305.00. By 10:27 AM, it traded at ₹1,310.85, a 0.02% increase, with a market cap of ₹1,09,399.38 crore.
Dr. Reddy’s launches novel drug Tegoprazan in India
Dr. Reddy’s Laboratories Ltd has launched a novel molecule, Tegoprazan, in India for acid-related gastrointestinal diseases. It is marketed under the brand name PCAB® in a 50 mg dosage form.
Tegoprazan is a potassium-competitive acid blocker. It is indicated for acid peptic diseases, including erosive and non-erosive GERD, and gastric ulcers. The drug provides rapid action and long-lasting gastric pH control.
Recent clinical trials by Dr. Reddy’s in India, South Africa, and Russia showed 99% GERD patients achieved healing by Week 8. Tegoprazan is approved in 21 countries, including South Korea and China.
Stock performance of Dr. Reddy’s Laboratories for Period of 1 week, 6 months, and 1 year
Dr. Reddy’s Laboratories Ltd delivered a 0.48% return over the past week, it gained 9.19% in the past six months. The stock declined 1.20% over the past year.
Also Read: John Cockerill: Stock jumps 3% after bagging ₹80 Cr contract from Tata Steel
Shareholding pattern of Dr. Reddy’s Laboratories
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 |
| Promoter | 27% | 27% | 27% |
| FII | 25.30% | 25.80% | 26.90% |
| DII | 37.80% | 37.20% | 36.10% |
| Public | 10.00% | 10.20% | 10.20% |
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd (NSE: DRREDDY) is a leading Indian pharmaceutical company providing APIs, generics, biosimilars, differentiated formulations, and custom pharmaceutical services across global markets, with a strong presence in healthcare innovation.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Dr. Reddy’s Laboratories Ltd share price going up today?
A: Dr. Reddy’s Laboratories Ltd share price is rising after launching Tegoprazan in India, marketed as PCAB® for acid-related gastrointestinal diseases.
Q: What does Dr. Reddy’s Laboratories Ltd specialize in?
A: Dr. Reddy’s Laboratories Ltd specializes in APIs, generics, biosimilars, differentiated formulations, and custom pharmaceutical services across multiple global healthcare markets.
Q: What is the 52-week high and low of Dr. Reddy’s Laboratories Ltd stock?
A: Dr. Reddy’s Laboratories Ltd stock recorded a 52-week high of ₹1,404.60 and a 52-week low of ₹1,025.90 in recent trading.
News Author
Aliceblue News Desk
